Novo Nordisk Cuts Prices on Ozempic, Wegovy

Novo Nordisk is reducing prices for Ozempic and Wegovy, offering a $199/month introductory price and lowering the 'typical' cost to $349/month. This makes them competitive with Lilly's Zepbound.

Nordisk’s discount rates come after both company’s reached a November 6 contract with the Trump administration to lower the expense following year for Wegovy and Zepbound to $350 per month on the TrumpRx portal, trending to $245 each month over a two-year duration. The medicines will likewise be available to Medicare and Medicaid recipients for the treatment of weight loss for the very first time.

Novo Nordisk’s Discounted Rates

Novo Nordisk revealed on Monday that, starting promptly, it is providing a two-month introductory cost of $199 a month for U.S.-based cash money buyers of its top-selling diabetes and fat burning drugs– Ozempic and Wegovy. It’s likewise reducing the “typical” cost for existing money customers to $349 a month from $499.

GLP-1 Hormone Targeting

Novo Nordisk and Lilly’s medications all work by targeting the GLP-1 hormonal agent that regulates cravings. The medications bring a sticker price of $1,000 and up each month, though significant price cuts and refunds are readily available to bring the price down.

Competitive Pricing with Zepbound

The discounts make Novo Nordisk’s medications price-competitive with Eli Lilly’s similar weight management drug Zepbound, which is readily available via the LillyDirect platform for $299 monthly at the lowest dose for cash-paying clients. Lilly is billing $449 monthly for its highest possible dosages, and Nordisk’s highest doses will certainly still set you back $499.

Novo Nordisk stated its cash-pay offers are available with the web sites Wegovy.com and Ozempic.com. They’re also accessible via the firm’s direct-to-consumer drug store, NovoCare; in addition to Costco, various telehealth suppliers, and greater than 70,000 pharmacies. The affordable two-month initial deal upright March 31.